Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

Details for Australian Patent Application No. 2008285652 (hide)

Owner Abbott GmbH & Co. KG

Inventors Lange, Udo; Unger, Liliane; Braje, Wilfried; Mezler, Mario; Wicke, Karsten; Mayrer, Matthias; Haupt, Andreas; Turner, Sean Colm; Drescher, Karla; Wernet, Wolfgang

Agent Spruson & Ferguson

Pub. Number AU-A-2008285652

PCT Pub. Number WO2009/019286

Priority 07113962.0 07.08.07 EP

Filing date 6 August 2008

Wipo publication date 12 February 2009

International Classifications

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/4709 (2006.01) - Non-condensed quinolines containing further heterocyclic rings

A61P 35/00 (2006.01) Antineoplastic agents

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

C07D 519/00 (2006.01) Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Event Publications

14 January 2010 PCT application entered the National Phase

  PCT publication WO2009/019286 Priority application(s): WO2009/019286

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008285655-Thiopeptide precursor protein, gene encoding it and uses thereof

2008285644-Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors